These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2708180)

  • 1. Cefixime, in-vitro activity, pharmacokinetics and tissue penetration.
    Stone JW; Linong G; Andrews JM; Wise R
    J Antimicrob Chemother; 1989 Feb; 23(2):221-8. PubMed ID: 2708180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefixime.
    Leggett NJ; Caravaggio C; Rybak MJ
    DICP; 1990 May; 24(5):489-95. PubMed ID: 2188437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
    Brogden RN; Campoli-Richards DM
    Drugs; 1989 Oct; 38(4):524-50. PubMed ID: 2684593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fundamental and clinical studies on cefixime in pediatrics].
    Iwai N; Shibata M; Mizoguchi F; Nakamura H; Katayama M
    Jpn J Antibiot; 1986 Apr; 39(4):1087-105. PubMed ID: 3761539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefixime: spectrum of antibacterial activity against 16,016 clinical isolates.
    Barry AL; Jones RN
    Pediatr Infect Dis J; 1987 Oct; 6(10):954-7. PubMed ID: 3696835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefixime shows good effects on group A and group B beta-haemolytic streptococci.
    Liberto MC; Carbone M; Fera MT; Berlinghieri MC; Puccio R; Focà A; De Luca M; Casini A
    Drugs Exp Clin Res; 1991; 17(6):305-8. PubMed ID: 1769318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parameters characterizing the in vitro activity of cefixime, a new oral broad spectrum cephalosporin, against respiratory and urinary pathogens.
    Debbia EA; Marchese A; Pesce A; Saverino D; Schito GC
    J Chemother; 1992 Jun; 4(3):131-44. PubMed ID: 1517806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of a new broad-spectrum, beta-lactamase-stable oral cephalosporin, cefixime, in comparison with other drugs, against Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis and Streptococcus pneumoniae.
    Stefani S; Pellegrino MB; D'Amico G; Privitera A; Privitera O; Maccarrone G; Russo G; Nicoletti G
    Chemotherapy; 1992; 38(1):36-45. PubMed ID: 1618002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefixime (CL284635) and other antimicrobial agents against Haemophilus isolates from pediatric patients.
    Kumar A; Kelly KJ
    Chemotherapy; 1988; 34(1):30-5. PubMed ID: 3258232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro effect of cefixime against Haemophilus influenzae].
    Dabernat H; Delmas C
    Presse Med; 1989 Oct; 18(32):1551-2. PubMed ID: 2530529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic and bactericidal characteristics of oral cefixime.
    Brittain DC; Scully BE; Hirose T; Neu HC
    Clin Pharmacol Ther; 1985 Nov; 38(5):590-4. PubMed ID: 4053491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fundamental and clinical studies on cefixime (5% granules) in the pediatric field].
    Toyonaga Y; Sugita M; Nakamura H; Joh K; Takahashi T; Kurosu Y; Hori M
    Jpn J Antibiot; 1986 Apr; 39(4):1055-75. PubMed ID: 3761537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of cefixime in healthy volunteers after a single oral administration of 200 mg].
    Montay G; Le Liboux A; Thebault JJ; Roche G; Frydman A; Gaillot J
    Presse Med; 1989 Oct; 18(32):1583-6. PubMed ID: 2530537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
    Nye K; Shi YG; Andrews JM; Ashby JP; Wise R
    J Antimicrob Chemother; 1989 Sep; 24(3):415-24. PubMed ID: 2808194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol.
    Carsenti-Etesse H; Farinotti R; Durant J; Roger PM; De Salvador F; Bernard E; Rouveix B; Dellamonica P
    Eur J Drug Metab Pharmacokinet; 1998; 23(3):357-66. PubMed ID: 9842977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.
    Bergeron MG; Turcotte A
    Antimicrob Agents Chemother; 1986 Dec; 30(6):913-6. PubMed ID: 3545070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibacterial effect of cefixime].
    Soussy CJ; Meyran M; Duval J
    Presse Med; 1989 Oct; 18(32):1546-50. PubMed ID: 2530528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.